Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
I’m ready to buy another swing position in the stinker. Come on $4.15
tell him soon or "$2s coming" cheers woof
Gavin just called me to ask for my preferred time line. What should I tell him?
32.07% daily short volume on Tuesday!
33.15% institutional ownership
32.07% daily short volume on Tuesday!
9.08 million shares (21.8% of the float) currently shorted
Current borrow fee: 83.5%
Shares available to borrow: 6000
32.07% of the daily volume has been shorted on Tuesday! Only 6000 shares are currently available for shorting (iborrowdesk) and the borrow fee is 83.5% - as soon as we get some decent volume, the shorts will get a serious problem! Any day from now we might get some more news and the manipulation by the shorts will finally come to an end! And this is all for a drug with a median extended life expectancy of more than 4 years and zero toxicity!! Let us hope that many cancer patients can soon profit from this revolutionary treatment! GLTAL! At most 18 days until we get some news from clinicaltrials.gov! Tick tock, tick tock ...
@Cat
Zero Mention of a Journal.
May not come any time soon.
Geert has not said anything besides "data will speak for itself"... but where is the data 1 year later?
Woof!
Cheers!
Remind me: Did he say the journal article has been submitted, or that they were in the journal selection process?
Thanks Captain obvious. What would we do w/o you? A little less noise please.
1 Yr Anniversary of Trial failing it’s primary end point
Was $30 now on way the $4.15
Cheers
"daily short volume"s meaningless intra-day order processing volume. Just MMs doing their job filling orders during the day.
Short INTEREST are open short positions needing to be bought back at some point in the future.
38.81% daily short volume but PPS up 1.56%!
33.15% institutional ownership
38.61% daily short volume on Monday but PPS up 1.56%!
9.08 million shares (21.8% of the float) currently shorted
Current borrow fee: 83.5%
Shares available to borrow: 6000
32.17% of the daily volume has been shorted on Monday but the PPS went up 1.56%! Only 6000 shares are currently available for shorting (iborrowdesk) and the borrow fee is 83.5% - as soon as we get some decent volume, the shorts will get a serious problem! Any day from now we might get some more news and the manipulation by the shorts will finally come to an end! And this is all for a drug with a median extended life expectancy of more than 4 years and zero toxicity!! Let us hope that many cancer patients can soon profit from this revolutionary treatment! GLTAL! At most 19 days until we get some news from clinicaltrials.gov! Tick tock, tick tock ...
A 10-day run up from some of our recent lows is not at all interesting for those playing for the endgame with CVM.
What will be interesting is the undeniable and sustained run-up once the FDA submission is done, the peer-reviewed publication is public and that data are undeniable, and once all those who follow fools like AdamF get their shorts *popped*.
ya, right. Up 40% in 10 days is not interesting at all. LOL
Nothing interesting or consistent is going to happen with CVM's share prices - up or down - until the company gets its FDA submission completed for review, or until after a peer-reviewed publication is accepted, or both.
Being in, or outside of the Russell index has no impact other than in the very short run.
Pre Market--7:01 AM EDT
$4.85
Up +0.36 (+8.02%)
Sorry. That’s a quote from Tony on yahoo.
Just passing it along
Cheers
CVM was dropped out of the Russell. They had to sell their shares. Nothing wrong with the company. Up for the week and up for the month.
Thought it would run again like the last few days, and it started the day that way.
.30 is a good entry. In case you did not know....."Kintara Therapeutics Granted Fast Track Designation from the FDA for VAL-083 for Newly-Diagnosed Glioblastoma"
Robert, you bought 5000 shares of a 30 cent stock? Why pre-market? Am I missing something.
I picked up 5k KTRA in pre market this morning. NWBO has released some of the data, met both end points, gonna fly very soon, just awaiting the published data. They had a talk in the UK yesterday, where DVax will be approved first. CVM seems to be moving on zero data, but I know that the secondary endpoint was met and Multikine is also a good, working drug. Combo trials will come (Dvax and Keytruda already a win/win), and some are already in progress with excellent results. All 3 stocks are a buy and hold IMHO. Best of luck.
Shabbat Shalom
With CVM being kicked of the Russell 2K index officially today, expect tons of volume
Off to Wisconsin, Door County specifically
Cheers
Nice, Robot! Good luck with the trifecta! I'm too invested in CVM to get into NWBO now. The price is nice, but I"m only peripherally aware of the NWBO story, and the large float is of concern to me - I've been burned a few times by reverse splits and such. I don't know anything about the other stock you mentioned, but I'm going to read up on it.
38.61% daily short volume but PPS up 13.18%!
33.15% institutional ownership
38.61% daily short volume on Thursday but PPS up 13.18%!
9.08 million shares (21.8% of the float) currently shorted
Current borrow fee: 117.0%
Shares available to borrow: 49
32.17% of the daily volume has been shorted on Thursday but the PPS went up 13.18%! Only 49 shares are currently available for shorting (iborrowdesk) and the borrow fee is 117.0% - as soon as we get some decent volume, the shorts will get a serious problem! Any day from now we might get some more news and the manipulation by the shorts will finally come to an end! And this is all for a drug with a median extended life expectancy of more than 4 years and zero toxicity!! Let us hope that many cancer patients can soon profit from this revolutionary treatment! GLTAL! Tick tock, tick tock ...
The spike high and somewhat below that show trading resistance...so it points to 6 to 6.50 area and the 200 day sma (6.89) as areas to consider....
Would be interesting to know if insiders have exercised.....and converted their expired options into a long position, right? They have 2 days to file a form 4...
I don't discuss my positions, so just my 2 cents.
$4.15 Foxwoods
Forgot a period
Cheers!
Woof!
Good thing I sold the stinker in the fives it’s now back in the fours I’ll wait till gets down to $415 before I buy back
Easiest stock to swing
Will buy back in low $4s
Cheers
A trifecta of brain cancer stocks on the rise, NWBO (6%), CVM (18%), KTRA (25%).
Thanks Guys
Sold last tranche of shares...
Ill take $28K profit in my Roth Account any day!
Sushi Out (until the next swing)
Cheers!
Wow... we haven't seen $5 in a long while!
Sush: Why don't you take a screen shot of your proof that you hold 36k. Then we might believe.
Go CVM
Will sell my 36K shortly
Cheers
32.17% daily short volume but PPS up 8.11%!
33.15% institutional ownership
32.17% daily short volume on Wednesday but PPS up 8.11%!
9.08 million shares (21.8% of the float) currently shorted
Current borrow fee: 91.2%
Shares available to borrow: 200
32.17% of the daily volume has been shorted on Wednesday but the PPS went up 8.11%! Only 200 shares are currently available for shorting (iborrowdesk) and the borrow fee is 91.2% - as soon as we get some decent volume, the shorts will get a serious problem! Any day from now we might get some more news and the manipulation by the shorts will finally come to an end! And this is all for a drug with a median extended life expectancy of more than 4 years and zero toxicity!! Let us hope that many cancer patients can soon profit from this revolutionary treatment! GLTAL! Tick tock, tick tock ...
Just kinda read his posts and move on...not a big deal.
he said he was stopped out last week. Today he says he added another 10,000 shares. Another of what? He didn't when he bought back in.
ADDING
Chart looks Geert!
Added another 10K just now to my swing position.
Cheers!
CHART LOOKS YUMMY
Swing Time
Cheers!
Yes, thanks for watching on these warrants....we;ll surely see ALL exercised on the form 4's in the following days....2 days after exercise for the insiders!
Yes, thanks for watch on these warrants....we;ll surely see ALL exercised on the form 4's in the following days....2 days after exercise for the insiders!
333,432 warrants at a price of $1.86 with a value of $620,183.52 expire today.
41.67% daily short volume but PPS up 3.56%!
33.15% institutional ownership
41.67% daily short volume on Tuesday but PPS up 3.56%!
9.08 million shares (21.8% of the float) currently shorted
Current borrow fee: 91.2%
Shares available to borrow: 200
41.67% of the daily volume has been shorted on Tuesday but the PPS went up 3.56%! Only 200 shares are currently available for shorting (iborrowdesk) and the borrow fee is 91.2% - as soon as we get some decent volume, the shorts will get a serious problem! Any day from now we might get some more news and the manipulation by the shorts will finally come to an end! And this is all for a drug with a median extended life expectancy of more than 4 years and zero toxicity!! Let us hope that many cancer patients can soon profit from this revolutionary treatment! GLTAL! Tick tock, tick tock ...
Cel-Sci Corporation (CVM)
https://www.youtube.com/watch?v=auAihG3rtC4
Multikine® (Leukocyte Interleukin, Injection) is the full name of this investigational therapy, which, for simplicity, is referred to in the remainder of this page as Multikine*.
Multikine, CEL-SCI's lead investigational immunotherapy, is an immunotherapeutic agent that is being developed as a potential first-line treatment for advanced primary head and neck cancer. If it were to be approved for use following completion of CEL-SCI's clinical development program, Multikine would be a different kind of therapy in the fight against cancer; one that appears to have the potential to work with the body's natural immune system in the fight against tumors.CANCER - MULTIKINE
Multikine may also have the potential to be a first in a new class of cancer immunotherapy drugs. It is the first investigational combination immunotherapy thought to have both passive and active immune properties. More...INFECTIOUS DISEASES - L.E.A.P.S.(TM)**
L.E.A.P.S is a patented, T-cell modulation, peptide epitope delivery technology that enables CEL-SCI to design and synthesize proprietary peptide immunogens. L.E.A.P.S. compounds consist of a small T-cell binding peptide ligand linked with a disease-associated peptide antigen.
This new technology has been shown the potential in several animal models to preferentially direct immune response to a cellular (e.g., T-cell), humoral (antibody) or mixed pathway. Diseases for which antigenic epitope sequences have been identified, such as some infectious diseases, cancer, autoimmune diseases, allergic asthma and allergy, and select CNS diseases (e.g., Alzheimer's) may be potential candidates for development using this technology platform. More...* Multikine is the trademark that CEL-SCI has registered for this investigational therapy, and this proprietary name is subject to FDA review in connection with our future anticipated regulatory submission for approval. Multikine has not been licensed or approved for sale, barter or exchange by the FDA or by any other regulatory agency. Similarly, its safety of efficacy has not been established for any use. Moreover, no definitive conclusions can be drawn from the early-phase, clinical-trials data summarized on this page or elsewhere on this website involving the investigational therapy Multikine (Leukocyte Interleukin, Injection). Further research is required, and early-phase clinical trial results must be confirmed in the well-controlled, Phase III clinical trial of this investigational therapy that is currently in progress.
** L.E.A.P.S. is the trademark of CEL-SCI for this investigational platform technology, and this proprietary name is subject to FDA review. No L.E.A.P.S. product has been approved for sale, barter or exchange by the FDA or any other regulatory agency for any use to treat disease in animals or humans. The safety or efficacy of these products has not been established for any use. Lastly, no definitive conclusions can be drawn from these early-phase, preclinical-trials data involving these investigational products
Partnering Philosophy & Corporate Partners
CEL-SCI's partnering philosophy is guided by the belief that any partnership entered into should serve the best interests of:
CEL-SCI is open to any reasonable partnership proposals that will accelerate its being able to bring its medicines to market.
Multikine (Leukocyte Interleukin, Injection) is the full name of this investigational therapy, which, for simplicity, is referred to in the remainder of this page as Multikine*.
CEL-SCI has a unique expertise in the development and manufacture of complex biologics. CEL-SCI is not a company that markets and sells drug products at the current time. Regardless, CEL-SCI believes it will be capable of marketing and selling Multikine on its own for head and neck cancer in both the United States and Europe if and once it is approved by the FDA (or EU regulators). Since its primary target is head & neck cancer surgeons, a rather small audience, CEL-SCI does not believe that a large sales force will be needed to commercialize Multikine, if and once it is approved by the FDA (or EU regulators) following the review of the total Multikine Biologics License Application.
Current Corporate Partners:
a. | Agreement Signed August 2008 | ||
b. | Territory - Israel, Turkey, expanded to also cover Serbia and Croatia in August 2011. | ||
c. | Revenue Share | ||
d. | Website - http://www.tevapharm.com/ |
a. | Agreement Signed November 2000 | ||
b. | Territory - Taiwan, Singapore, Hong Kong, Malaysia, expanded to also cover South Korea, the Philippines, Australia and New Zealand in the Fall of 2008. | ||
c. | Revenue Share | ||
d. | Website - http://www.oep.com.tw/ |
a. | Agreement signed August 2011 | ||
b. | Territory - Argentina and Venezuela | ||
c. | Revenue Share | ||
d. | Website - http://www.gp-pharm.com/ |
Based on the Company's L.E.A.P.S.TM** technology, as long as a disease epitope is available, CEL-SCI may be able to develop an effective treatment/vaccine using the L.E.A.P.S. technology. The two leading candidates derived from this technology are the H1N1 treatment being developed as a possible treatment option for hospitalized patients and the Rheumatoid Arthritis treatment vaccine currently being tested in animal models of the disease.
* Multikine is the trademark that CEL-SCI has registered for this investigational therapy, and this proprietary name is subject to FDA review in connection with our future anticipated regulatory submission for approval. Multikine has not been licensed or approved for sale, barter or exchange by the FDA or any other regulatory agency. Similarly, its safety or efficacy has not been established for any use. Moreover, no definitive conclusions can be drawn from the early-phase, clinical-trials data summarized on this page or elsewhere on this website involving the investigational therapy Multikine (Leukocyte Interleukin, Injection). Further research is required, and early-phase clinical trial results must be confirmed in the well-controlled, Phase III clinical trial of this investigational therapy that is currently in progress.
** L.E.A.P.S. is the trademark of CEL-SCI for this investigational platform technology, and this proprietary name is subject to FDA review. No L.E.A.P.S. product has been approved for sale, barter or exchange by the FDA or any other regulatory agency for any use to treat disease in animals or humans. The safety or efficacy of these products has not been established for any use. Lastly, no definitive conclusions can be drawn from these early-phase, preclinical-trials data involving these investigational products.
http://stockcharts.com/h-sc/ui?s=CVM&p=D&yr=3&mn=0&dy=0&id=p60195179833http://stockcharts.com/freecharts/gallery.html?CVM
http://finance.yahoo.com/q?s=cvm&ql=1
https://frugalnorwegian.com/cvm Insight into CVM P3 Trial Results
https://www.cvmresearch.com Insight into CVM P3 Trial Results & FDA Chances of Approval
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |